Molina Healthcare Q3 Earnings Miss Estimates on Rising Expenses

Molina Healthcare reported Q3 2025 adjusted EPS of $1.84, significantly missing analyst estimates of $3.97 and falling 69.4% year-over-year, despite an 11% revenue increase to $11.5 billion. The earnings miss was primarily driven by a 14.9% surge in operating expenses, pushing the medical care ratio to 92.6% from 89.2% a year prior. Consequently, the company dramatically lowered its full-year 2025 adjusted EPS guidance to approximately $14 from its previous forecast of at least $19, reflecting persistent pressure from rising medical care costs.

Analysis

Molina Healthcare (MOH) reported a significant earnings miss for Q3 2025, with adjusted EPS of $1.84 falling substantially short of the Zacks Consensus Estimate of $3.97 and representing a 69.4% year-over-year decline. This underperformance occurred despite an 11% year-over-year revenue increase to $11.5 billion, which surpassed consensus expectations. The primary driver for the earnings shortfall was a 14.9% surge in total operating expenses, elevating the consolidated medical care ratio (MCR) to 92.6% from 89.2% in the prior year, exceeding both consensus and internal estimates.

The increased medical care costs and general and administrative expenses severely impacted profitability, leading to a 72% year-over-year plunge in adjusted net income to $97 million. Financially, the company's cash and cash equivalents decreased to $4.2 billion from $4.7 billion at 2024-end, while long-term debt rose to $3.7 billion from $2.9 billion. Furthermore, Molina utilized $237 million in net cash from operating activities in the first nine months of 2025, a stark reversal from the $868 million generated in the same period of 2024.

In response to these pressures, management significantly revised its full-year 2025 adjusted EPS guidance downwards to approximately $14, a substantial reduction from the prior forecast of at least $19. While premium revenue guidance was slightly raised to $42.5 billion, the projected MCR of 91.3% indicates continued cost pressures. This negative outlook is reflected in the company's current Zacks Rank #5 (Strong Sell).

Key Decisions for Investors

• Investors should re-evaluate MOH positions given the substantial Q3 earnings miss, significant downward revision of full-year EPS guidance, and deteriorating profitability metrics.
• Monitor the medical care ratio (MCR) and operating expense trends closely, as these are critical indicators of the company's ability to manage costs and restore profitability.
• Consider the implications of increased long-term debt and negative operating cash flow, which signal potential balance sheet strain and reduced financial flexibility.